Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > AA and mBC

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 19, 2023 11:16am

143 Views

Post# 35503355

RE:RE:RE:RE:RE:RE:RE:RE:AA and mBC

For example - in Immunomedics/Gilead's Phase 3 TROPiCS-02 study that gained FDA approval for HR+/Her2 - mBC patients, Trodelvy was trialed against a comparator single-agent chemotherapy (treatment of physician’s choice) which was considered as the SOC. nothwithstanding that the enrolled patients had previouly received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.

https://www.gilead.com/news-and-press/press-room/press-releases/2023/2/us-fda-approves-trodelvy-in-pretreated-hrher2-metastatic-breast-cancer

<< Previous

Bullboard Posts

Next >>

Dollar Tree CEO Rick Dreiling steps down as discount retailer struggles